

1 **Serum extracellular vesicles trace COVID-19 progression and immune**
2 **responses**

3

4

5 Kevin Ho Wai Yim¹, Simone Borgoni¹ and Richard Chahwan^{1*}

6

7

8 ¹ Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

9

10

11

12

13 * **Corresponding author:** Richard Chahwan (chahwan@immunology.uzh.ch)

14

15

16 **Keywords:** COVID-19, SARS-CoV-2, extracellular vesicles, diagnosis, clinical liquid biopsy

17

18

19 **Word count:** ~ 5052

20

21

22 **ABSTRACT**

23 Coronavirus disease 2019 (COVID-19) has transformed very quickly into a world pandemic with
24 severe and unexpected consequences on human health. Concerted efforts to generate better
25 diagnostic and prognostic tools have been ongoing. Research, thus far, has primarily focused
26 on the virus itself or the direct immune response to it. Here, we propose extracellular vesicles
27 (EVs) from serum liquid biopsies as a new and unique modality to unify diagnostic and
28 prognostic tools for COVID-19 analyses. EVs are a novel player in intercellular signaling
29 particularly influencing immune responses. We herein show that innate and adaptive immune
30 EVs profiling, together with SARS-CoV-2 Spike S1⁺ EVs provide a novel signature for COVID-
31 19 infection. It also provides a unique ability to trace the co-existence of viral and host cell
32 signatures to monitor affected tissues and severity of the disease progression. And provide a
33 phenotypic insight into COVID-associated EVs.

34

35

36

37 INTRODUCTION

38 Coronavirus disease 2019 (COVID-19) was first identified in December 2019 in Wuhan, China.

39 The disease progressed into a global pandemic with over 64 million confirmed cases and over

40 3.9 million confirmed deaths as of June 2021^[1]. COVID-19 patients can be asymptomatic, suffer

41 from mild symptoms such as fever, cough, and dyspnea or develop into severe conditions

42 characterized as acute respiratory distress syndrome (ARDS) requiring mechanical ventilation^[2].

43 SARS-CoV-2, a positive-sense, single-stranded RNA virus, is known as the causative pathogen

44 of COVID-19. The commonly acknowledged mechanism of SARS-CoV-2 pathology is the entry

45 of viruses into angiotensin-converting enzyme 2 (ACE2) expressing host cells, with a tropism for

46 different organs, such as the respiratory tract, kidneys, liver, heart, brain, and blood vessels^[3].

47 SARS-CoV-2 infected cells can recruit different immune cell types and induce innate

48 inflammatory responses as well as adaptive immune responses mediated by targeted

49 antibodies. Sars-CoV-2 specific immunoglobulins (Ig) types M, A, and G have been used as an

50 indicator of protective immunity in infected patients. However, such antibody responses

51 normally emerge around 10 to 21 days after infection and may take even longer (four weeks or

52 more) in mild cases to be detected^[4]. In general, around 5 % of COVID-19 patients develop

53 severe conditions like ARDS, which arises around one week after symptom onset. Therefore,

54 SARS-CoV-2 specific antibody titer measurement is not the best predictor of severe disease for

55 infected patients who show mild symptoms early after infection but rapidly develop ARDS.

56 Extracellular vesicles (EVs) are nanosized lipid-bilayer vesicles that carry nucleic acid and

57 protein cargo. They are constitutively secreted by virtually all types of cells and circulate in most

58 biofluids such as blood, urine, saliva, and breast milk. Since the surface markers and molecular

59 cargo of EVs can reflect the cellular origin and activation status, they have been utilized as non-

60 invasive biomarkers from liquid biopsies in the past decade, for diagnostic and prognostic

61 purposes^[5-7]. Thanks to the lipid-bilayer structure of EVs, they are intrinsically more stable than

62 naked circulating molecules such as antibodies and cytokines, conferring a higher potential to

63 provide a more robust and long-lasting effect on the host immune response. Here, we
64 characterized serum EVs from healthy donors, early COVID-19 patients (< 13 days from
65 symptom onset), and late COVID-19 patients with mild disease (> 13 days from symptom onset),
66 in terms of size distribution, concentration and surface marker profile using nanoparticle flow
67 analyzer (NanoFCM[®]) [8]. Cluster analysis of different EVs subpopulations based on surface
68 marker expression was performed to identify signatures of healthy donors, early COVID-19 and
69 late COVID-19 patients. Lastly, COVID-19 specific SARS-CoV-2 Spike S1⁺ serum EVs were
70 characterized in relation to disease progression and host immune responses to determine
71 disease severity.

72

73

74 **RESULTS**

75 *Multiplex profiling of serum EVs derived from mild COVID-19 patients*

76 To explore the landscape of serum immune EVs during SARS-CoV-2 infection, we sampled a
77 cohort of 20 mild COVID-19 patients and 17 healthy donors (Table 1). According to the WHO
78 definition (World Health Organization, 2020), all the sampled COVID-19 patients in this study
79 experienced mild illness with symptoms such as fever, fatigue, or dyspnea. Serum EVs were
80 isolated from the whole blood of donors and patients. Purified serum EVs were analyzed by
81 nanoparticle analyzer to examine the size distribution and concentration of different serum EVs
82 subsets with a dedicated panel of immune markers and tetraspanins marker (Fig. 1A).

83 According to MISEV 2018 guideline, the physical properties of EVs, such as particle size
84 distribution and concentration were analyzed to ensure the reproducibility of the result.
85 Moreover, for diagnostic interest, potential variance in particle size distribution of different serum
86 EVs subsets between healthy controls and COVID-19 patients might provide valuable predictive
87 information (Fig. S1a). Using a mixture of four different sizes (66, 91, 113, 155 nm) of
88 monodisperse silica nanoparticles (refractive index = 1.461), we applied 4 size interval bins

89 based on the 4 separated side-scatter burst areas to quantify the approximate size distribution
90 of serum EVs, abbreviated as small, medium, large, extra-large accordingly (Fig. S1b). In
91 COVID-19 patients small EVs were more enriched, and CD66b⁺ EVs showed an increase
92 compared to healthy controls ($p < 0.05$, $p < 0.01$ respectively). However, extra-large EVs were
93 reduced in CD63⁺, CD38⁺, IgA⁺, IgG⁺ EVs in COVID-19 patients compared to healthy controls (p
94 < 0.05) (Fig. 1B, C, S1d).

95 Immune cells profiling of COVID-19 patients revealed numerous alterations in both innate and
96 adaptive immunity. However, whether immune cells derived EVs were influenced by COVID-19
97 or involved in any form of disease specific responses remains unknown. Canonical leukocyte
98 marker CD45 was first examined in patient serum EVs to gain an overview of immune EVs
99 changes in COVID-19. Interestingly, CD45⁺ serum EVs showed a significant reduction in mild
100 COVID-19 patients compared to healthy control (Fig. S1c). We next visualized the alteration of
101 CD45⁺ EVs levels against days post symptoms onset. Significant depletion in CD45⁺ EVs in
102 patients between 3 to 13 days post symptoms onset was observed compared to healthy
103 controls ($p < 0.05$). Strikingly, patients after 13 days post symptoms onset displayed a recovery
104 of CD45⁺ EVs level comparable to healthy controls. This finding highlighted the importance to
105 dissect the analysis into pre- and post-13 days post symptoms onset to gain more precise
106 perspectives in the serum EVs dynamics in COVID-19. Interestingly, depletion of CD45⁺ EVs in
107 the early onset of COVID-19 correlated to CD45⁺ cells deficiency observed in severe COVID-19
108 patients reported by another study ^[9], indicating the high sensitivity and early detection capacity
109 of EVs based diagnostics. Total EVs concentration did not show significant differences
110 suggesting the alteration in CD45⁺ EVs level was independent of total EVs production during
111 SARS-CoV-2 infection (Fig. 1C, D). The correlation between sizes and markers in EVs subsets
112 between healthy controls and COVID-19 patients was visualized by Spearman's rank correlation
113 matrix (Fig. 1E). A significant correlation of large and extra-large CD31⁺ EVs (predominantly
114 expressed by endothelial tissues) and total EVs was observed in healthy controls and post-13

115 days patients but not in pre-13 days patients. There was also a strong correlation between the
116 small CD14⁺, CD19⁺, CD56⁺ and CD63⁺ EVs in pre-13 days patients which were not present in
117 healthy controls nor post-13 days patients. These data suggest that classical monocytes-, B
118 cells- and natural killer cells-derived small EVs are predominantly affected in the early stage of
119 COVID-19.

120

121 *Detection of SARS-CoV-2-Spike S1⁺ serum EVs*

122 ACE2 containing EVs have been reported to prevent infection by SARS-CoV-2 virus indicating
123 the relevance of EVs in COVID-19 progression^[10]. Moreover, SARS-CoV-2 Spike S1 containing
124 EVs have been shown to serve as decoys for neutralizing antibodies^[11]. To explore whether
125 SARS-CoV-2 utilizes such strategies to influence disease progression and interaction with the
126 host, we attempted to detect and profile Spike S1⁺ serum EVs in this cohort of patients. To
127 eliminate the possibility of virus contamination in serum EVs purification, viral RNA detection by
128 PCR was performed with patients' serum and none of the specimens tested positive. Specificity
129 of Spike S1 antibody has been validated with negative control HEK293A and Spike S1
130 transfected HEK293A and their released EVs, in combination with serial titration of staining
131 cocktail with recombinant Spike S1 proteins (Fig. S2).

132 Spike S1⁺ EVs were detected in a small subset of healthy controls, suggesting their serum EVs
133 might be carrying cross-reactive epitopes that bind to Spike S1 antibodies used in the study. We,
134 therefore, applied a cut-off of Spike S1 fluorescence signal at 1.75% of total particles to exclude
135 all healthy controls. 5 out of 16 mild COVID-19 patients (dark blue dots in plots) had > 1.75%
136 Spike S1⁺ serum EVs (classified as Spike S1⁺ EVs positive), suggesting the existence of SARS-
137 CoV-2 specific EVs in human serum which could subsequently influence disease progression
138 (Fig. 2A). To further identify the origin of Spike S1⁺ EVs, we co-stained Spike S1 with a panel of
139 immune and endothelial markers since SARS-CoV-2 are known to significantly affect
140 endothelial tissues in patients^[12]. Notably, Spike S1⁺CD31⁺ EVs levels were significantly

141 increased in pre-13 days COVID-19 group compared to healthy controls and post-13 days
142 COVID-19, but not with the immune markers analyzed (Fig. S3). Elevated levels of endothelial
143 markers including CD31 were reported in COVID-19^[13], and temporary stress triggers CD31⁺
144 microparticle release^[14]. These data suggest Spike S1⁺ EVs likely originate from SARS-CoV-2
145 infected endothelial tissues. Total CD31⁺ EVs level also showed an elevating tendency in
146 COVID-19 patients compared to healthy controls. Reduction of small Spike S1⁺ EVs was also
147 observed in post-13 days patients compared to pre-13 days patients (Fig. 2B).

148 To gain deeper insights into the relationship between serum EVs and disease status, we applied
149 principal component analysis of serum EVs subset level across the cohort (Fig. 2C). A biplot
150 revealed the contribution of different EVs subsets as arrows showing the significant association
151 of CD45⁺ EVs and healthy controls. A quartile was dominated by pre-13 days patients and
152 highly associated with Spike S1⁺ EVs. A quartile with mostly post-13 days was defined by high
153 levels of CD31⁺ and CD63⁺ EVs. In another quartile, a heterogeneous mix of predominantly
154 healthy controls was defined by high levels of CD4⁺, CD14⁺, CD19⁺ and CD56⁺ EVs. Individuals
155 PCA clustering allowed the stratification of disease status based on frequencies of different EVs
156 subsets across the cohort. Taken together, despite the anticipated diversity across individuals
157 and less pronounced phenotypes in mild COVID-19 compared to severe ones, these
158 exploratory analyses enable the usage of serum EVs to predict disease status on top of
159 canonical clinical approaches (Fig. 2D).

160 To further probe the alterations of different serum EVs subsets during COVID-19, we applied
161 hierarchical clustering in a correlation map of serum EVs subsets across the cohort (Fig. 2E). In
162 the healthy controls group, specialized immune cell derived EVs, CD4⁺, CD14⁺, CD19⁺ and
163 CD56⁺ EVs had a strong positive correlation with each other but negatively correlate with CD45⁺
164 EVs, suggesting, in healthy state, immune EVs are less likely to originate from lymphocytes nor
165 monocytes but other types of leukocytes (i.e., neutrophils, around 60% of leukocytes in blood).
166 However, such negative correlation did not persist in COVID-19 patients, indicating the surge of

167 lymphocytes and monocytes driven responses during SARS-CoV-2 infection. Significant
168 positive correlation was also observed between CD38⁺ and IgG⁺ EVs in healthy controls but not
169 in any COVID-19 group. In the pre-13 days mild COVID-19 group, CD31⁺ and CD63⁺ EVs
170 started to positively correlate with specialized immune EVs. Strong positive correlation of Spike
171 S1⁺ and Spike S1⁺CD31⁺ EVs and negative correlation of CD19⁺ and CD66b⁺ EVs were also
172 observed. In the post-13 days mild COVID-19 group, the strong positive correlation between
173 specialized immune EVs was reduced as well as the correlation of Spike S1⁺ and Spike
174 S1⁺CD31⁺ EVs. In the overall mild COVID-19 group, regardless of time after symptoms onset,
175 specialized immune EVs positively correlate with CD31⁺ EVs and Spike S1⁺ EVs also positively
176 correlate with Spike S1⁺CD31⁺ EVs. In summary, the analysis of serum EVs cluster signatures
177 in relation to disease status and time after symptoms onset uncovered the dynamic patterns of
178 serum EVs subset levels during COVID-19 progression.

179

180 *Abundance of SARS-CoV-2-Spike S1 serum EVs indicate host immunological responses*

181 To better understand the dynamics of Spike S1⁺ EVs during SARS-CoV-2 infection, we
182 visualized the alteration of Spike S1⁺ and Spike S1⁺CD31⁺ EVs across the cohort against time
183 after symptoms onset (Fig. 3A). Spike S1⁺ EVs positive patients were present mostly in pre-13
184 days post symptoms onset, two of which from day 10 showed high Spike S1⁺CD31⁺ EVs (Fig.
185 3A). To explore the immunological relevance of serum Spike S1⁺ EVs during COVID-19
186 progression, we analyzed the SARS-CoV-2 specific immunoglobulins levels across the cohort
187 and in relation to time after symptoms onset (Fig. 3B). SARS-CoV-2 specific IgA and IgG levels
188 were below 0.6 G/l in all healthy controls and showed an increasing trend close to 10 days post
189 symptom onset (Fig. 3B, 3C). Two of the Spike S1⁺ EVs positive patients at day 10 showed
190 elevated levels of SARS-CoV-2 specific IgA and IgG (up to 24 and 3 G/l respectively) which are
191 predominantly observed in severe COVID-19 cases, suggesting the dynamics Spike S1⁺ EVs
192 levels in patients could provide sensitive detection of alternated immunological responses.

193 Levels of immunosuppressive cytokine IL-10^[15], one of the hallmarks observed in severe
194 COVID-19 was compared across the cohort. IL-10 levels were comparable between healthy
195 controls and COVID-19 patients, indicating cytokine secretion was not significantly affected in
196 this cohort of mild COVID-19 patients (Fig. 3D).

197 To further understand the relationship between Spike S1⁺ EVs and other significantly altered
198 factors between healthy controls and COVID-19 patients, we performed direct correlation
199 analysis between the levels of Spike S1⁺ EVs and Spike S1⁺CD31⁺ EVs, viral specific
200 immunoglobulins (IgG1 and IgG3) and immunosuppressive IL-10 (Fig. 3E). A strong positive
201 correlation was observed between Spike S1⁺ EVs and Spike S1⁺CD31⁺ EVs ($r = 0.6$, $p = 0.017$),
202 suggesting the Spike S1⁺ EVs are likely to originate from endothelial tissues. We also found a
203 strong negative correlation between Spike S1⁺ EVs and IgG1 ($r = -0.46$, $p = 0.036$) and IgG3 (r
204 $= -0.75$, $p = 0.0013$). In contrast to SARS-CoV-2 specific IgA and IgG, IgG1 and IgG3 are
205 predominantly induced by viral infection, with IgG3 appearing first during infection^[16]. These
206 negative correlations indicate levels of Spike S1⁺ EVs could estimate whether the host antibody
207 mediated responses are SARS-CoV-2 specific. Another negative correlation was observed
208 between Spike S1⁺ EVs and immunosuppressive IL-10, suggesting patients with higher Spike
209 S1⁺ EVs are less prone to immunosuppression of the immune system and possibly a lower
210 chance of disease deterioration.

211

212 *Mild COVID-19 patients derived serum EVs affect healthy PBMCs responses ex vivo*

213 Immune cells derived soluble factors such as IFN- γ , IL6, and TNF are known to cause
214 inflammation in severe COVID-19 cases and subsequently cause complications in the disease.
215 Since EVs have been shown to modulate immune responses in viral infection, we sought to
216 explore the possibility of EVs mediated immune regulation in COVID-19. B cells mediated
217 antibodies neutralization and T cells mediated cytokines production are the key drivers of host
218 immune defenses against COVID-19, understanding B and T cells responses in the presence of

219 purified serum EVs from the cohort would enable us to better understand the immune regulatory
220 network in COVID-19. To understand such mechanism, we activated healthy PBMC CD19⁺ B
221 cells (with IL-4 and IL-21) and CD3⁺ T cells (anti-CD3/CD28 and PMA/Ionomycin) *ex vivo* in the
222 presence of PBS control and purified serum EVs across the cohort. Cell viability, activation,
223 antibodies class switching (in B cells), and cytokine production (in T cells) were measured 4
224 days after activation by flow cytometry (Fig. 4A).

225 Viability of CD19⁺ B cells was consistent across the serum EVs in the cohort. Activation marker
226 CD86 expression was reduced in pre-13 days COVID-19 derived EVs compared to both healthy
227 controls and post-13 days COVID-19 derived EVs, suggesting serum EVs from pre-13 days
228 suppress B cells activation. IgM expression was similar across the serum EVs in the cohort
229 while IgA expression was significantly increased in post-13 days COVID-19 EVs, implying post-
230 13 days COVID-19 EVs promote antibodies class switching.

231 Viability of CD4⁺ T cells was reduced in pre-13 days COVID-19 derived EVs compared to post-
232 13 days COVID-19 derived EVs but not observed in CD8⁺ T cells. Activation marker CD69
233 expression in CD4⁺ and CD8⁺ T cells was similar across the serum EVs in the cohort. Significant
234 reduction of TNF production in CD4⁺ T cells was observed in pre-13 days COVID-19 EVs, with a
235 reducing tendency in post-13 days COVID-19 EVs compared to healthy controls. However, TNF
236 production in CD8⁺ T cells was comparable across the serum EVs in the cohort, suggesting
237 CD4⁺ T cells are more susceptible to serum EVs modulation. IFN- γ production of CD4⁺ and
238 CD8⁺ T cells was increased in pre-13 days COVID-19 EVs compared to both healthy controls
239 and post-13 days COVID-19 derived EVs. Taken together, serum EVs from COVID-19 patients
240 are capable to influence B and T cells responses in a targeted manner that possibly contribute
241 to the immune phenotypes observed in COVID-19 patients (Fig. 4B).

242

243

244 **DISCUSSION**

245 Throughout the COVID-19 pandemic, immune cell-profiling studies continue showing a wide
246 spectrum of immunological complications from mild to severe cases such as lymphopenia,
247 hyper inflammation and series of cytokine storms. Aside from studied soluble immune factors
248 like antibodies and cytokines, EVs are emerging as novel and potent intercellular signaling
249 mediators. EV cargos are under study as predictive tools for COVID-19 severity^[17-19]. However,
250 such recent studies required mass spectrometry and RNA-seq of EVs cargo which is not easy
251 to convert into routine clinical diagnostics due to the tedious processing and high expertise
252 required. Or they studied covid related EVs *ex vivo* ^[11]. We focus here on i) serum immune-
253 derived EVs because immune cells are predominantly found in the bloodstream, as are their
254 released EVs; ii) viral-specific EVs to gain specificity and viral tracking ability; iii) on analyzing
255 early- and late- mild covid patients to study the effect of the virus with minimal symptom
256 complications; and iv) attributing phenotypic functions for COVID-19 associated EVs. Therefore,
257 our analysis has consequences that surpass the basic investigation of COVID-19 biomarkers
258 per se and instead tries to trace the dynamic response of the virus and our body's response to it.
259

260 To harness the full potential of immune EVs in COVID-19, we applied multi-parametric EVs
261 phenotyping to characterize total EVs and specific immune associated subsets. The high
262 sensitivity and resolution of NanoFCM[®] used in this study allowed the possibility of direct single
263 EVs phenotyping. We could simultaneously measure and correlate EV size, concentration and
264 marker subset quantification; surpassing the conventional antibody coated beads approach
265 currently used^[20]. General enrichment of small EVs (~ 66 nm) in mild COVID-19 patients was
266 observed and more evident in total serum EVs and CD66b⁺, CD38⁺, IgA⁺, IgG⁺ EVs.
267 Interestingly, such enrichment of small EVs seems to correlate with reduction in extra-large EVs
268 (~ 155 nm) and is more pronounced in CD63⁺ EVs and CD66b⁺ EVs. Immunological studies
269 have shown inflammatory phenotypes in granulocytes (expressing CD66b) are one of the
270 strongest discriminators between non-infected and infected individuals as well as between

271 severity status of COVID-19 patients^[21]. The size shifts we observed correspond to the
272 moderate enrichment of smaller EVs due to cellular stress reported by others^[22]. Our results
273 suggest that EV's biogenesis machinery in general especially granulocytes may have been
274 altered by SARS-CoV-2 infection causing cellular stress. Although the underlying mechanism of
275 such phenotype is yet to be determined, it is conceivable that this is partly due to the interaction
276 between SARS-CoV-2 and the endosomal sorting complexes required for EV transport^[23].
277 Moreover, size distribution correlation maps revealed a strong positive association between
278 small specialized immune cells derived EVs (CD14⁺, CD19⁺, CD56⁺; classical monocytes, B
279 cells, NK cells) in pre-13 days after symptoms onset, suggesting these immune compartments
280 were potentially more stressed in the early phase of COVID-19. Another highlight in our study is
281 the depletion of leukocyte-derived CD45⁺ EVs in early phase of mild COVID-19 (pre-13 days).
282 Although our EV data is supported by studies measuring CD45 cell counts^[9], we also observed
283 a recovery of CD45⁺ EV levels in the latter phase of mild COVID-19 (post-13 days). Given the
284 predominant 14 days COVID-19 isolation guidelines^[24], and the fact that these patients were all
285 mildly symptomatic our data bolsters the ability of our study to dynamically trace covid19
286 progression based on immune EVs. This also may reflect the partial recovery of host immune
287 systems as reflected by serum EVs markers. It is worth noting that by combining pre- and post-
288 13 days data these small dynamic immune changes can counter-weight each other and be lost
289 to measurements, which suggest that future work should consider infection time or disease
290 onset as a factor. Moreover, biplot cluster analysis showed insignificant variance of EVs subsets
291 distribution between age groups and sex of donors (Fig. S4).

292

293 Engineered EVs expressing SARS-CoV-2 antigens, such as ACE2 and Spike S1, have been
294 shown to perform potent functions in inhibiting coronavirus infection and serving as decoys for
295 neutralizing antibodies, respectively^[10,11]. These findings not only prove the potential relevance
296 of EVs in COVID-19 progression but also highlight the possibility of SARS-CoV-2 utilizing EVs

297 as an intermediate driver for replication and interplay with host immune defenses. Within our
298 cohort of mild COVID-19 patients, almost one-third showed significantly elevated Spike S1⁺ EVs
299 level in our platform when compared to healthy controls. The existence of Spike S1⁺ EVs in
300 patients' serum – which we show for the first time and which seems to peak 8-12 days post
301 symptoms – strongly support the potential of SARS-CoV-2 exploiting host EVs to act as decoys
302 for neutralizing antibodies and evade from the host immune surveillance and specific responses
303 as anticipated in an *in vitro* study of artificial Spike S1⁺ EVs^[11]. Moreover, the possibility to
304 detect SARS-CoV-2 Spike S1 marker from patients' serum EVs and profile their dynamics
305 during course of infection provided a novel tool for disease specific EVs phenotyping in both
306 research and clinical applications, especially in monitoring life-threatening severe COVID-19
307 progression. Throughout our panel of immune markers and endothelial marker co-stained with
308 Spike S1 across the cohort, Spike S1⁺CD31⁺ EVs levels were significantly altered in pre-13
309 days COVID-19 compared to healthy controls. These data support the notion that endothelial
310 tissues (predominantly expressing CD31) were significantly influenced by SARS-CoV-2 infection,
311 but also suggesting a notable amount of Spike S1⁺ EVs originate from endothelial tissues.
312 Further studies with staining of additional markers as well as future development on high
313 dimensional single EVs analysis shall provide a more conclusive representation of serum EVs
314 subsets distribution not only in COVID-19, but also other viral infections and diseases.

315 Within our dataset, a global PCA analysis of analyzed EVs subsets distribution across the
316 cohort displayed a clear stratification between healthy controls, pre-, and post- 13 days of
317 COVID-19. The partial overlap between pre-13 and post-13 days revealed the core serum EVs
318 features associated with the SARS-CoV-2 infection and might be explained by the 'long COVID'
319 observed in other follow-up studies^[25,26]. Despite the overlap, post-13 days COVID-19 were less
320 separated from pre-13 days COVID-19 indicating the gradual normalization of analyzed serum
321 EVs, possibly associated with their parental cells and tissues. From the correlation clustering of
322 EVs subsets across the cohort, we could show distinct serum EVs signatures that enable

323 differentiation between healthy controls and COVID-19 patients as well as tracing the
324 progression of COVID-19.

325 Furthermore, correlation of Spike S1⁺ EVs and SARS-CoV-2 specific IgA, IgG, IL-10, IgG1 and
326 IgG3 revealed the clinical implications of Spike S1⁺ EVs levels in the context of host immune
327 responses and disease progression. Within our dataset, Spike S1⁺ EVs positive patients tend to
328 show higher SARS-CoV-2 specific antibody responses and lower levels of immunosuppressive
329 IL-10, which in theory, should result in less disease deterioration. Negative correlation between
330 Spike S1⁺ EVs and generic viral induced IgG1 and IgG3 responses^[16] implies that Spike S1⁺
331 EVs levels could indicate the chances of developing SARS-CoV-2 specific responses in an early
332 predictive manner, and subsequently, enable more precise and prompt treatment decision in the
333 clinics.

334
335 Our functional assay of purified serum EVs in *ex vivo* PBMC B and T cells activation
336 demonstrated novel perspectives of the biological relevance and influences of COVID-19
337 derived serum EVs. The significant increase in IgA⁺ B cells in the presence of post-13 days
338 COVID-19 EVs indicates certain EV subsets derived from later phase of COVID-19, are partially
339 facilitating B cell antibody class switching during COVID-19 progression. Our dataset also aligns
340 with the elevated IFN- γ levels observed in severe COVID-19 patients^[27], IFN- γ enrichment in
341 CD4⁺ T cells in the presence of pre-13 days COVID-19 EVs but not post-13 days COVID-19
342 EVs. This dataset suggests that early in SARS-CoV-2 infection, infected host cells were
343 possibly reprogrammed to produce certain EVs subsets to promote inflammatory IFN- γ
344 production in CD4⁺ T cells. Interestingly, despite TNF elevation were observed in other clinical
345 studies of severe COVID-19 patients^[28], we found significant depletion of TNF in CD4⁺ T cells in
346 the presence of pre-13 days COVID-19 EVs, suggesting serum EVs from early phase of
347 COVID-19 are suppressive for TNF production in CD4⁺ T cells. Taken together, our findings

348 provide an initial stepping-stone for the field to understand EVs signaling mediated COVID-19
349 progression.

350
351 With the rather small cohort size and limited markers combinations, the predictive values of
352 serum EVs could be further bolstered and fully exploited in clinical applications. Future work
353 shall consider increasing the size of cohort with the addition of severe patients from various
354 group cohorts including age, sex, genetic, geographical background, and treatment courses.
355 Moreover, to enhance the diagnostic and prognostic specificity of serum EVs in COVID-19,
356 future work shall include sampling from non-SARS-CoV-2 infected individuals such as seasonal
357 influenza patients. This approach will allow us to better stratify the EVs subsets signatures
358 between COVID-19 and general flu-like viral infections and ultimately fortify clinical predictive
359 value of EVs. Indeed, future optimization of high-dimensional spectral analyzers for EVs
360 characterization with the addition of more immune and viral markers will broaden our spectrum
361 to better trace the dynamics of host immune responses as well as disease progression. In the
362 therapeutic context, our functional assay demonstrated the feasibility of utilizing serum EVs from
363 different disease severity to manipulate host immune responses. Nevertheless, identification of
364 responsible EVs subsets and understanding their mode of action are essential for us to harvest
365 their therapeutic potentials in the future.

366
367 The dynamics of serum EVs subsets distribution highlighted their predictive values in the
368 perspectives of overall host immune responses and correlation between disease specific Spike
369 S1⁺ EVs and immune responses during COVID-19 progression. The study strengthens the
370 potential of serum EVs based diagnostic and prognostic, potentially therapeutic applications in
371 COVID-19, and easily transferred to other types of viral infections and cancers.

372

373

374 MATERIALS AND METHODS

375 *Study subjects*

376 Peripheral blood was draw from healthy donors and COVID-19 patients recruited at the
377 University Hospital Zurich (Switzerland) outpatient clinic. The patients were eligible if they were
378 symptomatic at the time of inclusion, had a newly diagnosed SARS-CoV-2 infection confirmed
379 by quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR), and were over 18
380 years old. Healthy donors (n = 17) were recruited as controls. All participants, patients and
381 healthy controls, signed a written informed consent. This non-interventional, observational study
382 was approved by the Cantonal Ethics Committee of Zurich (BASEC #2016-01440) and
383 performed in accordance with the Declaration of Helsinki. The sample size was based on
384 availability of the samples. Investigators were blinded to disease severity, while performing
385 experiments. While the analysis was cross-sectional, the patient outcomes were recorded
386 prospectively after inclusion. Standard clinical laboratory data (CRP, LDH, complete blood count
387 with differential) was collected from the first day of hospitalization. Patients were classified
388 according to WHO guidance into mild cases (n=20) in the same hospital laboratory. All healthy
389 controls were tested for SARS-CoV-2 specific IgA and IgG antibodies, and all were below the
390 diagnostic reference value. All patients received a standard clinical laboratory sampling and
391 cytokines were measured. Furthermore, samples from 20 mild COVID-19 patients and all
392 healthy subjects were processed for nano flow analysis and *ex vivo activation of PBMCs*. Briefly,
393 3 – 5 mL of peripheral venous blood was collected from into BD Vacutainer serum clot activator
394 10 ml (367896). After collection, tubes were left vertically undisturbed on the bench for 15
395 minutes to allow blood clot and followed by centrifugation at 2,500 g for 10 mins at 4°C for
396 separation of sera. The supernatant was collected into a new tube and the serum samples were
397 stored at 4°C until use. Due to the limited number of available samples, certain serum samples
398 did not have enough amount for all the immunostaining panels.

399

400 *Isolation of serum EVs for phenotyping analysis and functional assays*

401 1 mL of serum samples were first diluted with 9 mL of PBS and concentrated using Amicon®
402 ultra-0.5 centrifugal filter devices (Millipore, Amicon® Ultra 100 K device) at 3,000 g for 30 mins
403 at 4°C. Serum retentate (100 uL per patient) was diluted with 1.4 mL of PBS and subjected to
404 centrifugation at 10,000 g for 30 mins at 4°C. The 10k pellet was resuspended in 1.5 mL PBS
405 and subjected ultracentrifugation at 120,000 g for 90 mins at 4°C (F50L-24x1.5 rotor). The pellet
406 was resuspended in 50 uL PBS and stored at 4°C until use.

407 *Nano flow analysis of serum EVs*

408 The configuration NanoFCM® used in the study was performed as described in another study^[20].
409 10 uL of purified serum EVs were subjected to immunofluorescence staining using antibodies
410 listed in supplementary materials (Table 1) at the concentration of 1 in 200 uL for 1 hour at 4°C
411 covered in dark. Immuno-stained serum EVs were washed by ultracentrifugation at 120,000 g
412 for 90 mins at 4°C, pellet was resuspended in 50 uL PBS for nano flow analysis. Monodisperse
413 silica nanoparticles of four different sizes, with modal peak sizes of 66 nm, 91 nm, 113 nm and
414 155 nm were used as the size reference standard to calibrate the size distribution of EVs.

415

416 *Ex vivo activation of PBMCs*

417 Buffy coats were obtained from Blutspende Zurich, Schlieren, Switzerland (BASEC #2019-
418 00837). PBMCs were isolated using Ficoll-Paque density gradient centrifugation. CD19⁺ B cells
419 were isolated using STEMCELL EasySep™ Release Human CD19 Positive Selection Kit
420 according to manufacturer's instruction. CD19⁺ B cells were activated with both human
421 recombinant IL-4 and IL-21 at 10 ng/mL (Biolegend). Remaining cell suspension were plated in
422 RPMI-1640 media supplemented in 10% heat inactivated fetal bovine serum (FBS) (Sigma) and
423 1% penicillin streptomycin/glutamine (Thermo) for 24 hours at 37°C, 5% CO₂. Cells were
424 collected at 300 g for 5 mins and stimulated with anti-CD3/CD28 beads at 1 bead per cell

425 (Thermo). 50 uL of purified serum EVs from healthy controls, pre-13 days and post-13 days mild
426 COVID-19 were added to cultured cells together with stimulatory agents.

427
428 *Cell cultures transfection and flow cytometry for SARS-CoV-2 Spike S1 staining controls*
429 HEK293A cells were grown in 10 cm tissue culture dishes in DMEM (Sigma) supplemented with
430 10% heat-inactivated FBS and 1% penicillin/streptomycin. To generate Spike S1 expressing
431 HEK293A cells and EVs, we transfected HEK293A cells with pCMV14-3X-Flag-SARS-CoV-2 S
432 plasmid (Addgene #145780) together with GFP plasmid (for transfection efficiency quantification)
433 and EVs were collected 24 hours post transfection from conditioned medium using serial
434 centrifugation as noted above. Transfection efficiency of HEK293A was measured by flow
435 cytometry (BD Canto II) in the FITC channel. To test the antibody binding specificity, prior to
436 immunostaining of Spike S1 on cells and EVs, molar ratios of 0:1, 1:1, 2:1, 5:1 of recombinant
437 Spike S1 proteins (Sino Biological, #40591-V08H) were incubated with anti-Spike S1 for 30
438 mins at 4°C to neutralize unbound antibodies. Resulting staining cocktail (with range of
439 neutralizing recombinant Spike S1 proteins) were used to stain non-transfected and Spike S1
440 transfected HEK293A and EVs for 1 hour at 4°C covered in dark. Spike S1 signals were
441 detected by flow cytometry (HEK293A) and nano flow analyzer (EVs).

442
443 *Data and statistical analysis*

444 Both cells and EVs flow cytometry data were exported as FCS files and analyzed using Flowjo
445 software. Statistical analysis of clinical diagnostic and flow cytometry values were performed
446 using Graphpad (version 9.1.1, GraphPad Software, La Jolla California USA). Ordinary One-
447 way ANOVA, P-value < 0.05 was considered as statistical significance. PCA and biplot were
448 generated with R software (version 4.0.1) using the package 'factoextra' and 'ggplot2'.
449 Spearman's correlation analyses were produced using the corrplot package and implemented

450 hclust method. The correlations between different EVs subsets, and between different disease
451 severity group were analyzed using non-parametric Spearman correlations. The significance
452 threshold was set at $\alpha < 0.05$.

453

454

455

456 **ACKNOWLEDGMENT**

457 We sincerely thank Prof Onur Boyman and Dr Carlo Cervia for providing critical elements for
458 this study including clinical samples, data, and insightful comments. We thank Dr Ben Peacock
459 for NanoFCM sample support. RC is supported by BBSRC (BB/N017773/2), SNF (CRSK-
460 3_190550; IZSEZO_204655), and the UZH Research Priority Program (URPP Translational
461 Cancer Research). KY is supported by a Bio & MedTech Entrepreneur Fellowship.

462

463

464 **AUTHOR CONTRIBUTIONS**

465 KY and RC conceived the idea and coordinated the project. RC secured funding and guided the
466 work. KY performed experiments and analyses. KY and SB performed in vitro experiments and
467 statistical data analyses. KY wrote the manuscript draft, which was then finalized by KY and RC
468 with the assistance of SB.

469

470

471 **DECLARATION OF INTERESTS**

472 All authors have declared that no conflict of interest exists.

473

474

475

476 **REFERENCES**

- 477 [1] E. Dong, H. Du, L. Gardner, *Lancet Infect. Dis.* **2020**, *20*, 533.
- 478 [2] Z. Wu, J. M. McGoogan, *JAMA - J. Am. Med. Assoc.* **2020**, *323*, 1239.
- 479 [3] V. G. Puelles, M. Lütgehetmann, M. T. Lindenmeyer, J. P. Sperhake, M. N. Wong, L.
480 Allweiss, S. Chilla, A. Heinemann, N. Wanner, S. Liu, F. Braun, S. Lu, S. Pfefferle, A. S.
481 Schröder, C. Edler, O. Gross, M. Glatzel, D. Wichmann, T. Wiech, S. Kluge, K. Pueschel,
482 M. Aepfelbacher, T. B. Huber, *N. Engl. J. Med.* **2020**, *383*, 590.
- 483 [4] C. Cervia, J. Nilsson, Y. Zurbuchen, A. Valaperti, J. Schreiner, A. Wolfensberger, M. E.
484 Raeber, S. Adamo, S. Weigang, M. Emmenegger, S. Hasler, P. P. Bosshard, E. De
485 Cecco, E. Bächli, A. Rudiger, M. Stüssi-Helbling, L. C. Huber, A. S. Zinkernagel, D. J.
486 Schaer, A. Aguzzi, G. Kochs, U. Held, E. Probst-Müller, S. K. Rampini, O. Boyman, *J.*
487 *Allergy Clin. Immunol.* **2021**, *147*, 545.
- 488 [5] K. H. W. Yim, A. Al Hrouf, S. Borgoni, R. Chahwan, *Cancers (Basel)*. **2020**, *12*, 1.
- 489 [6] H. BF, B.-Y. G. M, W. S, L. JC, *Adv. Sci. (Weinheim, Baden-Wurttemberg, Ger.* **2020**, *7*,
490 DOI 10.1002/ADVS.202002596.
- 491 [7] B. KA, Y. S. B, A. AD, M. M. P, W. M, M. PY, *Front. Immunol.* **2020**, *11*, DOI
492 10.3389/FIMMU.2020.00022.
- 493 [8] S. AM, L.-I. E, G. A, D. A, D. G, P. B, O. X, S. N, F. KP, S. O, D. N, *J. Extracell. vesicles*
494 **2021**, *10*, DOI 10.1002/JEV2.12130.
- 495 [9] M. Jin, N. Shi, M. Wang, C. Shi, S. Lu, Q. Chang, S. Sha, Y. Lin, Y. Chen, H. Zhou, K.
496 Liang, X. Huang, Y. Shi, G. Huang, *Aging (Albany. NY)*. **2020**, *12*, 19867.
- 497 [10] F. Coccozza, N. Névo, E. Piovesana, X. Lahaye, J. Buchrieser, O. Schwartz, N. Manel, M.
498 Tkach, C. Théry, L. Martin-Jaular, *J. Extracell. Vesicles* **2020**, *10*, DOI
499 10.1002/jev2.12050.
- 500 [11] Z. Troyer, N. Alhusaini, C. O. Tabler, T. Sweet, K. I. L. Carvalho, D. M. Schlatzer, L.
501 Carias, C. L. King, K. Matreyek, J. C. Tilton, *J. Extracell. Vesicles* **2021**, *10*, e12112.
- 502 [12] J. H. Levy, T. Iba, E. E. Gardiner, *Arterioscler. Thromb. Vasc. Biol.* **2021**, *41*, 1774.
- 503 [13] A. Birnhuber, E. Fliesser, G. Gorkiewicz, M. Zacharias, B. Seeliger, S. David, T. Welte, J.
504 Schmidt, H. Olschewski, M. Wygrecka, G. Kwapiszewska, *Eur. Respir. J.* **2021**, 2100377.
- 505 [14] M. Lichtenauer, B. Goebel, M. Fritzenwanger, M. Förster, S. Betge, A. Lauten, H. R.
506 Figulla, C. Jung, *Clin. Hemorheol. Microcirc.* **2015**, *61*, 83.
- 507 [15] H. Han, Q. Ma, C. Li, R. Liu, L. Zhao, W. Wang, P. Zhang, X. Liu, G. Gao, F. Liu, Y. Jiang,
508 X. Cheng, C. Zhu, Y. Xia, *Emerg. Microbes Infect.* **2020**, *9*, 1123.
- 509 [16] G. Vidarsson, G. Dekkers, T. Rispens, *Front. Immunol.* **2014**, *5*, DOI

- 510 10.3389/fimmu.2014.00520.
- 511 [17] Y. Fujita, T. Hoshina, J. Matsuzaki, Y. Yoshioka, T. Kadota, Y. Hosaka, S. Fujimoto, H.
512 Kawamoto, N. Watanabe, K. Sawaki, Y. Sakamoto, M. Miyajima, K. Lee, K. Nakaharai, T.
513 Horino, R. Nakagawa, J. Araya, M. Miyato, M. Yoshida, K. Kuwano, T. Ochiya, *J.*
514 *Extracell. Vesicles* **2021**, *10*, e12092.
- 515 [18] K. Mao, Q. Tan, Y. Ma, S. Wang, H. Zhong, Y. Liao, Q. Huang, W. Xiao, H. Xia, X. Tan, P.
516 Luo, J. Xu, D. Long, Y. Jin, *Cell Death Dis.* **2021**, *12*, 541.
- 517 [19] C. Balbi, J. Burrello, S. Bolis, E. Lazzarini, V. Biemmi, E. Pianezzi, A. Burrello, E.
518 Caporali, L. G. Grazioli, G. Martinetti, T. Fusi-Schmidhauser, G. Vassalli, G. Melli, L.
519 Barile, *EBioMedicine* **2021**, *67*, 103369.
- 520 [20] Y. Tian, M. Gong, Y. Hu, H. Liu, W. Zhang, M. Zhang, X. Hu, D. Aubert, S. Zhu, L. Wu, X.
521 Yan, *J. Extracell. Vesicles* **2020**, DOI 10.1080/20013078.2019.1697028.
- 522 [21] J. Vitte, A. B. Diallo, A. Boumaza, A. Lopez, M. Michel, J. Allardet-Servent, S. Mezouar, Y.
523 Sereme, J. M. Busnel, T. Miloud, F. Malergue, P. E. Morange, P. Halfon, D. Olive, M.
524 Leone, J. L. Mege, *J. Infect. Dis.* **2020**, *222*, 1985.
- 525 [22] O. G. de Jong, M. C. Verhaar, Y. Chen, P. Vader, H. Gremmels, G. Posthuma, R. M.
526 Schiffelers, M. Gucek, B. W. M. van Balkom, *J. Extracell. Vesicles* **2012**, *1*, DOI
527 10.3402/jev.v1i0.18396.
- 528 [23] M. V. Veetil, B. Kumar, M. A. Ansari, D. Dutta, J. Iqbal, O. Gjyshi, V. Bottero, B.
529 Chandran, *J. Virol.* **2016**, *90*, 3860.
- 530 [24] K. A. Walsh, S. Spillane, L. Comber, K. Cardwell, P. Harrington, J. Connell, C. Teljeur, N.
531 Broderick, C. F. de Gascun, S. M. Smith, M. Ryan, M. O'Neill, *J. Infect.* **2020**, *81*, 847.
- 532 [25] M. Merad, J. C. Martin, *Nat. Rev. Immunol.* **2020**, *20*, 355.
- 533 [26] K. E. Bernstein, Z. Khan, J. F. Giani, D. Y. Cao, E. A. Bernstein, X. Z. Shen, *Nat. Rev.*
534 *Nephrol.* **2018**, *14*, 325.
- 535 [27] I. E. Galani, N. Rovina, V. Lampropoulou, V. Triantafyllia, M. Manioudaki, E. Pavlos, E.
536 Koukaki, P. C. Fragkou, V. Panou, V. Rapti, O. Koltsida, A. Mentis, N. Koulouris, S.
537 Tsiodras, A. Koutsoukou, E. Andreakos, *Nat. Immunol.* **2021**, *22*, 32.
- 538 [28] P. C. Robinson, D. Richards, H. L. Tanner, M. Feldmann, *Lancet Rheumatol.* **2020**, *2*,
539 e653.
- 540
- 541

542 **FIGURE LEGENDS**

543 **Table 1.** Demographic and clinical characteristics of the patient cohort.

544

545 **Figure 1.** Characterization of immune serum EVs in healthy controls and mild COVID-19
546 patients. (A) Schematic outline of EVs profiling from denoted human samples. (B) Size
547 distribution quantification of serum EVs from denoted human samples and different EV subsets,
548 with size reference beads with a mixture of four modal sizes of 66 nm (small), 91 nm (medium),
549 113 nm (large), 155 nm (extra-large). Representative side scatter histogram of size reference
550 beads in (B) and total serum EVs from denoted human samples on the right. (C, D)
551 Quantification of total serum EVs and CD45+ EVs in denoted human samples at days of
552 reported symptom onset. (E) Spearman's rank correlation matrix of size distribution of serum
553 EVs subsets between healthy donors and mild COVID-19 patients. One-way ANOVA, $p < 0.05$ *,
554 $p < 0.01$ **, $p < 0.005$ ***.

555

556 **Figure 2.** Characterization of Sars-Cov-2 Spike S1+ serum EVs in healthy controls and mild
557 COVID-19 patients. (A) Quantification of Spike S1+, Spike S1+CD31+ and CD31+ serum EVs in
558 denoted human samples, dark blue (Spike S1+ EVs positive). (B) Size distribution quantification
559 of serum EVs from denoted human samples and indicated EV subsets. (C) Bi-plot and principal
560 component analysis of set of serum EVs markers defining healthy and mild COVID-19 status. (D)
561 Spearman's rank correlation matrix of serum EVs subsets between healthy donors and mild
562 COVID-19 patients. One-way ANOVA, $p < 0.05$ *, $p < 0.01$ **, $p < 0.005$ ***.

563

564 **Figure 3.** Correlation of Sars-Cov-2 Spike S1+ serum EVs with host immune responses in
565 healthy controls and mild COVID-19 patients. (A) Quantification of Sars-Cov-2 Spike S1+ and
566 Sars-Cov-2 Spike S1+CD31+ EVs in denoted human samples at days after reported symptom
567 onset. (B, C) Quantification of soluble Sars-Cov-2 specific immunoglobulins in denoted human
568 samples at days after reported symptom onset. (D) Quantification of soluble interleukin-10
569 levels in denoted human samples at days after reported symptom onset. (E) Spearman's
570 correlation of level of Spike S1+ serum EVs to Spike S1+CD31+ EVs, soluble IgG1, IgG3 and
571 interleukin-10 levels.

572

573 **Figure 4.** Mild COVID-19 patients derived serum EVs affect healthy PBMCs responses *ex vivo*
574 (A) Schematic outline of *ex vivo* healthy PBMCs activation in the presence of PBS control and
575 serum EVs from healthy donors and mild COVID-19 patients. (B-D) Quantification of different

576 subsets expansion, activation, cytokine production (T cells) (C, D) and class switch
577 recombination (B cells) (B). One-way ANOVA, $p < 0.05$ *, $p < 0.01$ **, $p < 0.005$ ***.

578

579 SUPPLEMENTARY FIGURE LEGENDS

580

581 **Figure S1.** Nanoflow control and experimental setup. (A) Representative nanoflow gating
582 strategies of EVs, HEK293A derived EVs (control) and representative patient derived serum
583 EVs. (B) Representative back gating strategies to determine size distribution of EV subsets
584 using size reference beads with mixture of four modal sizes, 66 nm (small), 91 nm (medium),
585 113 nm (large), 155 nm (extra-large). (C) Quantification of CD45⁺ serum EVs in healthy controls
586 and mild COVID-19 patients. (D) Quantification of size distribution of CD38⁺, IgA⁺, IgG⁺ serum
587 EVs in healthy controls and mild COVID-19 patients.

588

589 **Figure S2.** Binding specificity of Sars-CoV-2 Spike S1 antibodies. (A) Representative flow
590 gating strategies of HEK293A co-transfected with GFP and Spike S1 plasmid after 24 hours. (B)
591 Competition of anti-Spike S1 binding in HEK293A in (A) with addition of recombinant Spike S1
592 proteins in denoted molar ratio. (C) Representative flow gating strategies of EVs derived from
593 HEK293A co-transfected with GFP and Spike S1 plasmid after 24 hours and competition of anti-
594 Spike S1 binding in EVs with addition of recombinant Spike S1 proteins in denoted molar ratio.

595





596 **Figure S3.** (A) Representative flow gating strategies of patient derived serum EVs for Spike S1
597 and CD31. (B) Quantification of Spike S1⁺CD45⁺, Spike S1⁺CD38⁺, Spike S1⁺CD56⁺, Spike
598 S1⁺IgA⁺, Spike S1⁺IgG⁺, Spike S1⁺CD66b⁺ serum EVs in in healthy controls and mild COVID-19
599 patients.

600



601 **Figure S4.** PCA plot clustering of serum EVs samples based on age (A) and sex (B).






Table 1. Demographic and clinical characteristics of the patient cohort.




	Healthy	Mild COVID-19	
No. of samples	17	20	
Median age [years]	31	34	
Gender (M/F)	7/10	11/9	
Time since symptom onset (days)	-	11 ± 5.01996	
Laboratories values			P value
Hemoglobin(mean ± SD, [g/l])	143.13 ± 11.76	81.35 ± 75.79	0.0028
Absolute platelet count(mean ± SD, [G/l])	252 ± 50.71	243.25 ± 61.79	ns
Total white blood cell count mean ± SD, [G/l])	6.06 ± 1.73	5.13 ± 1.14	ns
Monocytes(mean ± SD, [G/l])	0.45 ± 0.16	0.46 ± 0.1	ns
Neutrophils(mean ± SD, [G/l])	3.61 ± 1.29	2.64 ± 0.91	0.0129
Eosinophils(mean ± SD, [G/l])	0.1 ± 0.05	0.12 ± 0.09	ns
Basophils(mean ± SD, [G/l])	0.05 ± 0.01	0.03 ± 0.01	0.0015
Lymphocytes(mean ± SD, [G/l])	1.84 ± 0.56	1.85 ± 0.56	ns
CD3- CD56bright CD16dim NK cells (mean ± SD, [cells/ul])	18.47 ± 5.35	12.1 ± 5.7	ns
CD3- CD56dim CD16bright NK cells (mean ± SD, [cells/ul])	164.59 ± 119.87	248.25 ± 131.75	ns
CD4+ T cells(mean ± SD, [cells/ul])	376.24 ± 468.03	780.3 ± 290.92	0.0029
CD19+ B cells(mean ± SD, [cells/ul])	101.41 ± 130.44	189.4 ± 103.36	0.0282
C-reactive protein(mean ± SD, [mg/l])	1.04 ± 0.97	1.74 ± 1.89	ns
LDH(mean ± SD, [U/l])	332.24 ± 53.88	342.39 ± 79.04	ns
IL-6(mean ± SD, [pg/ml])	0.47 ± 0.57	2.51 ± 4.24	ns
IL-10 (mean ± SD, [pg/ml])	1.15 ± 1.3	1.64 ± 2.19	ns
IFN γ (mean ± SD, [pg/ml])	0.88 ± 1.68	1.89 ± 2.64	ns
TNF α (mean ± SD, [pg/ml])	7.32 ± 3.04	8.36 ± 3.49	ns
Anti-CoV-2 IgA(mean ± SD, [μ g/mL])	0.34 ± 0.18	4.85 ± 7.2	0.0144
Anti-CoV-2 IgG(mean ± SD, [μ g/mL])	0.27 ± 0.15	1.03 ± 0.92	0.0019
Comorbidities			
Hypertonia - no. (%)	-	-	
Diabetes - no. (%)	-	-	
Heart disease - no. (%)	-	1 (5%)	
Lung disease - no. (%)	-	-	
Malignancy - no. (%)	-	-	
Immunosuppression - no. (%)	-	-	
Kidney disease - no. (%)	-	-	
Cerebrovascular disease - no. (%)	-	-	
M Crohn - no. (%)	-	1 (5%)	
Allergic asthma - no. (%)	-	2 (10%)	
Hypothyreose - no. (%)	1 (6%)	3 (15%)	

A**B****C****D****E**


EVs subset size correlation




A**B****C****D****E****EVs subsets correlation**

A**B****C**


A



B



C



D

